MedPath

Effectiveness of IRK-19® on Body Weight Control

Not Applicable
Completed
Conditions
Overweight
Metabolic Syndrome
Interventions
Dietary Supplement: Pumpkin seed extract (IRK-19)
Registration Number
NCT05542160
Lead Sponsor
Greenyn Biotechnology Co., Ltd.
Brief Summary

This randomized, double-blind, placebo-controlled, and parallel clinical study aims to investigate the effectivness of a pumpkin seed extract (IRK-19®) on weight management.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  1. BMI: 25-30 kg/m2
  2. Waistline circumference: ˃ 80 cm
Exclusion Criteria
  1. Pregnant women or preparing for pregnancy.
  2. Lactating women.
  3. Women gave birth 6 months before the study.
  4. Subject uses diuretic, corticosteroids, anti-depressant medications, or antipsychotic medications.
  5. Subject has undertaken obesity-related surgeries within one year prior to the study or other surgeries within six months prior to the study.
  6. Change of body weight of subject is over 5% within 3 months before the study.
  7. Subject has serious diseases (e.g., cardiovascular diseases).
  8. Cancer patient.
  9. Subject has engaged in another study within 3 months before the study.
  10. Subject uses another dietary supplement related to weight management during the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPumpkin seed extract (IRK-19)Placebo capsule
TreatmentPumpkin seed extract (IRK-19)IRK-19 capsule
Primary Outcome Measures
NameTimeMethod
BiochemistryWeek 12

Insulin

Anthropometric measurementWeek 12

Hip circumference

Body composition analysisWeek 12

Subcutaneous fat

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

WanFang Hospital

🇨🇳

Taipei City, Taiwan

© Copyright 2025. All Rights Reserved by MedPath